
Syrayeva Gulnara
St-Petersburg State Medical University , Russian FederationTitle: Socioeconomic burden of the use of non-steroid anti-inflammatory drugs in Russia. example - Paracetamol
Abstract
Annotation: The group of
non-steroidal anti-inflammatory drugs (NSAIDs) is one of the most popular
medications in Russian Federation. The high level of consumption is explained
by the wide range of indications for use and wide availability, which in turn
leads to uncontrolled and unreasonable use and the development of events
associated with issues of pharmacological safety of patients.
Aim: Assessment of
the socio-economic burden of adverse drug reactions for non-steroidal
anti-inflammatory drugs using the example of the international non-proprietary
name (INN): paracetamol
Materials and
methods: In this article
calculations of the socio-economic burden of the use of NSAIDs are modeled
using the example of the paracetamol.
The national database «Pharmacovigilance» was used as a register of adverse
drug reactions when paracetamol was used. During assessing the burden, direct
medical costs (payment for a completed case of inpatient treatment, stay in the
resuscitation and intensive care unit, calling an ambulance), direct
non-medical costs (payment of benefits on a disability certificate) were taken
into account. The source of information on prices was: compulsory health
insurance tariffs, price lists of state and commercial clinics.
Conclusions: Direct medical
costs, which included the development of the "best" scenario for
pharmacotherapy with paracetamol for the period from 2010 to 2020 amounted to 10,277,410.60 rubles, when
calculating the main analysis, the costs of providing adverse drug reactions
were 13,108,219.20 rubles, in the framework of the “worst” scenario, the costs
amounted to 24,683,842.36 rubles. Thus, the development of the “best” scenario
will be 0.13% of the amount initially spent on pharmacotherapy with
paracetamol, in the framework of the main analysis - 0.17% and, in the
development of the "worst" scenario - 0.32%, which indicates that the
use of paracetamol is economically justified.
Biography
Syrayeva Gulnara graduated from St. Petersburg State Medical University named after I.I. Pavlova in 2010. Dr. Syrayeva has two specializations - infectious diseases and clinical pharmacology, has published more than 20 articles, she is a speaker at international conferences. In addition, she participates in the organization and conduct of clinical trials.